Home Cart Sign in  
Chemical Structure| 4079-26-9 Chemical Structure| 4079-26-9

Structure of PD146176
CAS No.: 4079-26-9

Chemical Structure| 4079-26-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PD 146176 is a specific, non-competitve 15-lipoxygenase (15-LOX) inhibitor with Ki of 197 nM.

Synonyms: NSC168807

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PD146176

CAS No. :4079-26-9
Formula : C15H11NS
M.W : 237.32
SMILES Code : C1(N2)=C(CSC3=CC=CC=C31)C4=C2C=CC=C4
Synonyms :
NSC168807
MDL No. :MFCD05664738
InChI Key :ZGOOPZVQMLHPFM-UHFFFAOYSA-N
Pubchem ID :297589

Safety of PD146176

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P310-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human bronchial epithelial cells 1 mM 10 days To evaluate the inhibitory effect of PD146176 on IL-13-induced MUC5AC expression. Results showed that PD146176 significantly suppressed IL-13-induced MUC5AC mRNA expression. Am J Respir Crit Care Med. 2009 May 1;179(9):782-90
DRG neurons 10 µM 15 minutes To investigate the inhibitory effect of PD146176 on LA-induced calcium responses, results showed that PD146176 significantly reduced the response of DRG neurons to LA. Br J Pharmacol. 2013 Apr;168(8):1961-74
Human lung macrophages 10 µM 24 hours To investigate the inhibitory effect of PD146176 on chemokine release induced by LPS and Th2 cytokines. Results showed that PD146176 significantly reduced the release of chemokines induced by LPS and Th2 cytokines. Br J Pharmacol. 2015 Sep;172(17):4319-30

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Alcoholic liver disease model Intraperitoneal injection 10 mg/kg Once daily for 7 days To test the therapeutic effect of PD146176 on alcoholic liver disease, results showed that PD146176 significantly alleviated alcohol-elevated plasma AST and ALT, diminished alcohol-induced liver histopathological changes, inhibited ROS production, and reduced hepatic lipid accumulation. Sci Rep. 2017 Aug 21;7(1):8976
Rats Pregnant rats Intraperitoneal injection 5 mg/kg Administered 1 h before each exposure for three consecutive days PD146176 mitigated sevoflurane-induced ferroptosis and subsequent cognitive impairment, reduced elevated MDA levels and significantly reduced iron overload, alleviated inhibition of GPX4 activity, and improved neural density and alignment of the CA1 region of the hippocampus during long-term development. CNS Neurosci Ther. 2023 Oct;29(10):2972-2985
Sprague Dawley rats Carrageenan-induced inflammatory pain model Intraplantar injection 50 µg/50 µL Single administration, observed for 4 hours To investigate the effect of PD146176 on inflammatory pain behavior, results showed that PD146176 significantly attenuated carrageenan-induced hyperalgesia. Br J Pharmacol. 2013 Apr;168(8):1961-74

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.21mL

0.84mL

0.42mL

21.07mL

4.21mL

2.11mL

42.14mL

8.43mL

4.21mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories